Cel
The 2022 Monkeypox outbreak is unprecedented in scale and cases are still active in South America and starting to appear in South-East Asia. Many questions about Monkeypox virus disease remain unanswered to this day, particularly concerning the management of patients. MPX-RESPONSE aims to increase our knowledge of the monkeypox virus disease, to improve its therapeutic management and to further inform public health policies and guidelines through four Work Packages (WP). WP2 (MOSAIC) will assess clinical and virological outcomes of Monkeypox patients treated or not with antiviral drugs, focusing treatment on the most severe cases. WPs 3 and 4 will conduct randomized clinical trials (RCT) with the most promising antiviral therapy, tecovirimat, targeting patients in Europe (WP3-EPOXI) and globally in collaboration with WHO (WP4-UNITY); particularly in mild and moderate cases. A common primary outcome will be shared between the two RCTs and EPOXI will include additional objectives regarding pharmacological, immunological and virological outcomes in six to ten EU/EEA countries and fulfill in particular EMA requirements for treatment authorisation. A continuous systematic review and individual patient meta-analysis will summarize all randomized evidence of the interventions for monkeypox. Finally, the project will make sure that acquired knowledge is integrated into public health policies and guidelines and that adequate messages are shared with the general public and high-risk populations with the help of patients’ representatives and associations (WP1-COORDINATE). To accomplish these objectives, MPX-RESPONSE will build on the expertise and networks of multiples partners including Ecraid and EU-RESPONSE and will reinforce and broaden Europe’s capacity to respond rapidly to public health emergencies.
Dziedzina nauki
Słowa kluczowe
Program(-y)
Zaproszenie do składania wniosków
Zobacz inne projekty w ramach tego zaproszeniaSystem finansowania
HORIZON-RIA - HORIZON Research and Innovation ActionsKoordynator
75654 Paris
Francja
Zobacz na mapie
Uczestnicy (13)
0450 Oslo
Zobacz na mapie
37129 Verona
Zobacz na mapie
75015 PARIS
Zobacz na mapie
75012 Paris
Zobacz na mapie
28046 MADRID
Zobacz na mapie
3584 BA Utrecht
Zobacz na mapie
Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant.
3584 CX Utrecht
Zobacz na mapie
2000 Antwerpen
Zobacz na mapie
3015 GD Rotterdam
Zobacz na mapie
21040 900 Rio De Janeiro
Zobacz na mapie
0456 Oslo
Zobacz na mapie
75015 Paris
Zobacz na mapie
C1202ABB BUENOS AIRES
Zobacz na mapie
Partnerzy (3)
Organizacje partnerskie biorą udział w realizacji działania, jednak nie podpisują umowy o grant.
4051 Basel
Zobacz na mapie
Organizacje partnerskie biorą udział w realizacji działania, jednak nie podpisują umowy o grant.
Zakończenie uczestnictwa
1205 Geneve 14
Zobacz na mapie
Organizacje partnerskie biorą udział w realizacji działania, jednak nie podpisują umowy o grant.
1211 Geneve
Zobacz na mapie